Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$81,667.00
A cost-effectiveness analysis of targeted therapy for HER2-positive breast cancer based on Canadian practice patterns
EF 2008-09
Résumé
The goal of this research endeavour is to demonstrate how disparities between health policy recommendations and actual practice can influence the cost-effectiveness of targeted cancer therapy and patient care. The example of trastuzumab for treatment of human epidermal growth factor receptor-2 (HER2/neu or HER2)-positive breast cancer will be employed given its established presence in Canadian therapy since receiving approval for treatment of metastatic breast cancer in 1998. The specific policy in question concerns the use of two approved diagnostic tests, each with differing costs and accuracy, to identify HER2-positive patients and to direct subsequent trastuzumab therapy. Different testing strategies, representing Canadian policy recommendations and alternative sequences and combinations of the two tests, will be compared to data reflecting actual practice within a decision-analytic framework. Then, treatment with trastuzumab will be modeled and the impact of false-positive and false-negative diagnoses produced by each test-treat strategy will be quantified. This analysis contributes new information to the literature by illustrating the value of using actual practice data in cost-effectiveness analysis. The quantification of any deviations from policy and practice recommendations will highlight the potentially serious consequences for patient care. This critical and pragmatic evaluation will also highlight the importance of considering the joint effects of diagnosis and treatment in evaluations of targeted therapy.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
184352
Name
Ferrusi Ilia L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
A cost-effectiveness analysis of targeted therapy for HER2-positive breast cancer based on Canadian practice patterns
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$81,667
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cost-Effectiveness Analysis; Decision-Analytic Modelling; Health Economics; Health Technology Assessment; Her2; Practice Patterns; Targeted Therapy; Value Of Information Analysis
Abstract
The goal of this research endeavour is to demonstrate how disparities between health policy recommendations and actual practice can influence the cost-effectiveness of targeted cancer therapy and patient care. The example of trastuzumab for treatment of human epidermal growth factor receptor-2 (HER2/neu or HER2)-positive breast cancer will be employed given its established presence in Canadian therapy since receiving approval for treatment of metastatic breast cancer in 1998. The specific policy in question concerns the use of two approved diagnostic tests, each with differing costs and accuracy, to identify HER2-positive patients and to direct subsequent trastuzumab therapy. Different testing strategies, representing Canadian policy recommendations and alternative sequences and combinations of the two tests, will be compared to data reflecting actual practice within a decision-analytic framework. Then, treatment with trastuzumab will be modeled and the impact of false-positive and false-negative diagnoses produced by each test-treat strategy will be quantified. This analysis contributes new information to the literature by illustrating the value of using actual practice data in cost-effectiveness analysis. The quantification of any deviations from policy and practice recommendations will highlight the potentially serious consequences for patient care. This critical and pragmatic evaluation will also highlight the importance of considering the joint effects of diagnosis and treatment in evaluations of targeted therapy.
Competitiondate
200810
Approvedterm2
2 yrs 4 mths
Pinamesdelim
Ferrusi, Ilia L
Approvedterm
2 ans 4 mois
Cihrcontribution2
~ $81,667~ $0~